Immutep (ASX:IMM) has announced that the investigator-initiated EFTISARC-NEO Phase 2 trial evaluating its eftilagimod alpha with radiotherapy plus MSD's KEYTRUDA (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint. …
Immutep’s efti combination meets primary endpoint in Phase 2 soft tissue sarcoma
May 26, 2025 Australian Biotech
Latest Video
New Stories
-
Specialised Therapeutics expands partnership with Incyte to include two additional therapies
June 13, 2025 - - Latest News -
New immunisation strategy highlights COVID impact, priority patients and new technologies
June 12, 2025 - - Latest News -
Medicines Australia establishes radiopharmaceuticals working group
June 12, 2025 - - Latest News -
MSD Australia and New Zealand certified a 'Great Place to Work'
June 12, 2025 - - Latest News -
Specialised Therapeutics expands partnership with Incyte to include two additional therapies
June 12, 2025 - - Latest News -
Novo Nordisk partners with Heart of Australia to expand clinical trial access
June 12, 2025 - - Latest News -
Mark Butler starts the process of NDIS pricing reform
June 11, 2025 - - Latest News